Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

August 4, 2026

Tempus' multimodal foundation model offers diagnostic-grade precision for cancer detection and unlocks broader applications predicting biomarker status and patient prognosis

CHICAGO--(BUSINESS WIRE)--Aug. 4, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft, can perform clinically important diagnostic tasks using simple prompts and can be leveraged for a variety of downstream applications. The results were published in *Nature Medicine*.

PRISM2 outperformed or matched existing slide-level foundation models across a comprehensive set of diagnostic, biomarker and patient outcome prediction tasks. Additionally, when further tuned to specifically predict long-term outcomes, PRISM2 outperformed standalone models, including achieving high performance predicting colorectal cancer recurrence-free survival.

"PRISM2 represents a true leap forward both in terms of scale and multi-modal AI capabilities," said Razik Yousfi, Senior Vice President and General Manager of AI Products at Tempus. “Our Pathology Foundation Models allow us to have a detailed understanding of tissue, unlocking clinical-grade precision and novel research applications capable of predicting patient outcomes and biomarker status. PRISM2 builds on this by aligning whole-slide pathology images with the language of clinical diagnosis through clinical dialogue training. It can seamlessly handle complex diagnostic and prognostic research tasks without requiring specialized fine-tuning, offering a powerful tool to advance precision oncology."

As part of Tempus’ proprietary Pathology Foundation Models, PRISM2 turns routine hematoxylin and eosin (H&E) slides into deep biological insights. By combining large vision models built from pathology images with large language models, it unlocks diagnostic-grade precision in research involving cancer detection, biomarker identification and prognosis prediction.

PRISM2 was trained on a diverse set of 2.3 million whole-slide images and 14 million diagnostic question−answer pairs derived from nearly 700,000 pathology reports, making it the largest multimodal slide-level pathology datasets to date.

To support ongoing research, open science, and other non-commercial and non-clinical use cases, the full PRISM2 model weights are publicly available through Hugging Face at https://huggingface.co/paige-ai/Prism2 and https://huggingface.co/paige-ai/Prism2-survival.

About Tempus AI

Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus’ research and publications; the contributions of Tempus’ research and findings to the larger scientific community and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260804131477/en/

Hanah Heintzelman
hanah.heintzelman@tempus.com

Source: Tempus AI, Inc.